 |
 |
 |
 |
|
 |
Treatment Next 25
|
 |
Location |
 |
Last Updated |
 |
 |
 |
Details |
 |
A Pilot Study to Evaluate the Effects of Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides in Combination with Poly-ICLC for Children with Newly Diagnosed Malignant or Intrinsic Brain Stem Gliomas (BSG) or Incompletely Resected Non-Brainstem High-Grade Gliomas (HGG) or Recurrent Unresectable Low-Grade Gliomas (LGG) or Recurrent High Grade Gliomas |
 |
Pittsburgh, PA |
 |
09/23/2009 |
 |
 |
 |
 |
 |
Details |
 |
Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor |
 |
Boston, MA |
 |
09/06/2009 |
 |
 |
 |
Details |
 |
Phase I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas
|
 |
Durham, NC |
 |
09/05/2009 |
 |
 |
 |
 |
 |
Details |
 |
ABTC07-01-Phase I Trial of Aflibercept (VEGF Trap) with Radiation Therapy and Concomitant and Adjuvant
Temozolomide in Patients with Malignant Glioma |
 |
San Francisco, CA |
 |
07/07/2009 |
 |
 |
 |
Details |
 |
A Phase I Trial and Pharmacokinetic Study of Trabectedin (Yondelis®, ET-743) in Children and Adolescents With Relapsed or Refractory Solid Tumors
|
 |
Bethesda, MD |
 |
04/22/2009 |
 |
 |
 |
 |
 |
Details |
 |
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
|
 |
Bethesda, MD |
 |
04/22/2009 |
 |
 |
 |
Details |
 |
A Phase I/II Trial of ZD6474 for Patients With Recurrent High-Grade and Progressive Low-Grade Gliomas
|
 |
Bethesda, MD |
 |
04/22/2009 |
 |
 |
 |
 |
 |
Details |
 |
Multiple Ascending Dose (MAD) Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Pediatric Patients With Advanced Solid Tumors.
|
 |
Bethesda, MD |
 |
04/22/2009 |
 |
 |
 |
Details |
 |
Phase II Trial of Tamoxifen and Bortezomib in Patients With Recurrent High-Grade Gliomas
|
 |
Bethesda, MD |
 |
04/22/2009 |
 |
 |
 |
 |
 |
Details |
 |
A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination With Temodar and Radiation Therapy in Patients With High Grade Gliomas
|
 |
Bethesda, MD |
 |
04/21/2009 |
 |
 |
 |
Details |
 |
A Phase II Trial of Bevacizumab (avastin) and Irinotecan (CPT-11) for Patients With Recurrent High-Grade Gliomas Immediately Following Tumor Progression After Treatment With Bevacizumab Alone: A Companion Trial to NCI Study 06-C-0064 (Bevacizumab Alone for Recurrent Gliomas)
|
 |
Bethesda, MD |
 |
04/21/2009 |
 |
 |
 |
 |
 |
Details |
 |
A Phase II Trial of Enzastaurin in Combination With Bevacizumab in Adults With Recurrent Malignant Gliomas
|
 |
Bethesda, MD |
 |
04/21/2009 |
 |
 |
 |
Details |
 |
Phase II Trial of Bevacizumab (Avastin)for Patients With Recurrent High-Grade Glioma |
 |
Bethesda, MD |
 |
04/21/2009 |
 |
 |
 |
 |
 |
Details |
 |
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
 |
Toronto, Ontario, CANADA Bethesda, MD New York, NY Cincinnati,, OH Columbus, OH |
 |
04/21/2009 |
 |
 |
 |
Details |
 |
An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-Grade Glioma |
 |
Bethesda, MD |
 |
04/15/2009 |
 |
 |
 |
 |
 |
Details |
 |
Phase I Trial of Conditionally Replication-Competent Adenovirus (Delta-24-RGD4C) for recurrent malignant glioma |
 |
Houston, TX |
 |
04/14/2009 |
 |
 |
 |
Details |
 |
A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas |
 |
San Francisco, CA |
 |
04/06/2009 |
 |
 |
 |
 |
 |
Details |
 |
Quality of Life in Patients with Brain Tumors, Skull Base Tumors & Pituitary Adenomas Undergoing Surgical Resection |
 |
Santa Monica, CA |
 |
11/29/2008 |
 |
 |
 |
Details |
 |
Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
|
 |
San Francisco, CA Washington, DC Chicago, IL Boston, MA Bethesda, MD Durham, NC Philadelphia, PA Pittsburgh, PA Memphis, TN Seattle, WA |
 |
11/08/2008 |
 |
 |
 |
 |
 |
Details |
 |
A Phase II Trial of Thalidomide in combination with Temozolomide or CPT-11 in patients with recurrent anaplastic gliomas or glioblastoma multiforme
|
 |
Houston, TX |
 |
10/27/2008 |
 |
 |
 |
Details |
 |
Phase I Trial of Aflibercept (VEGF Trap)with Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Malignant Gliomas |
 |
Los Angeles, CA San Francisco, CA Boston, MA Durham, NC New York, NY Pittsburgh, PA Houston, TX San Antonio, TX Madison, WI |
 |
10/27/2008 |
 |
 |
 |
 |
 |
Details |
 |
BIBW 2992 with or without daily temozolomide in the treatment of
patients with recurrent malignant glioma
|
 |
Charlottesville, VA |
 |
10/20/2008 |
 |
 |
 |
Details |
 |
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
|
 |
Boston, MA New York, NY Houston, TX Charlottesville, VA |
 |
10/09/2008 |
 |
 |
 |
 |
 |
Details |
 |
Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors |
 |
Charlottesville, VA |
 |
09/30/2008 |
 |
 |
 |
Details |
 |
Gliogene: An International Brain Tumor Study |
 |
Houston, TX |
 |
07/24/2008 |
 |
 |
 |
 |
 |